| Autor: |
Rey-Vargas L; Cancer Biology Research Group, National Cancer Institute, Bogotá 111411, Colombia.; Doctoral Program in Biological Sciences, Pontificia Universidad Javeriana, Bogotá 110231, Colombia., Bejarano-Rivera LM; Cancer Biology Research Group, National Cancer Institute, Bogotá 111411, Colombia., Ballen DF; Clinical Oncology Unit, National Cancer Institute, Bogotá 111411, Colombia., Serrano-Gómez SJ; Cancer Biology Research Group, National Cancer Institute, Bogotá 111411, Colombia.; Research Support and Follow-Up Group, National Cancer Institute, Bogotá 111411, Colombia. |
| Jazyk: |
angličtina |
| Zdroj: |
Cancers [Cancers (Basel)] 2024 Sep 12; Vol. 16 (18). Date of Electronic Publication: 2024 Sep 12. |
| DOI: |
10.3390/cancers16183141 |
| Abstrakt: |
HER2-low tumors have shown promise in response to antibody-drug conjugates (ADCs) in recent clinical trials, underscoring the need to characterize this group's clinical phenotype. In this study, we aimed to explore the clinicopathological features, survival rates, and HER2 amplicon mRNA expression of women affected with HER2-low breast cancer, compared with HER2-negative and HER2-positive groups. We included 516 breast cancer patients from Colombia, for whom we compared clinicopathological features, mRNA expression of three HER2 amplicon genes ( ERBB2, GRB7 and MIEN1 ), survival and risk of mortality between HER2-low cases (1+ or 2+ with negative in situ hybridization (ISH) result) with HER2-positive (3+ or 2+ with positive ISH test) and HER2-negative (0+) cases. A higher proportion of patients with better-differentiated tumors and a lower proliferation index were observed for HER2-low tumors compared to the HER2-positive group. Additionally, HER2-low tumors showed higher mRNA expression of the ERBB2 gene and longer overall survival rates compared to HER2-negative cases. Nonetheless, a Cox-adjusted model by ER status and clinical stage showed no statistically significant differences between these groups. Our results show differences in important clinicopathological features between HER2-low and both HER2-positive and negative tumors. Given this unique phenotype, it is crucial to evaluate the potential advantages of ADC therapies for this emerging subtype of breast cancer. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
|
Nepřihlášeným uživatelům se plný text nezobrazuje |
K zobrazení výsledku je třeba se přihlásit.
|
